Moderna, Inc. $MRNA Stock: Illinois Municipal Retirement Fund Raises Stake

Illinois Municipal Retirement Fund raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 12.3% in the third quarter, HoldingsChannel reports. The firm owned 115,726 shares of the company’s stock after acquiring an additional 12,721 shares during the period. Illinois Municipal Retirement Fund’s holdings in Moderna were worth $22,285,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Moderna in the second quarter valued at approximately $2,142,877,000. Theleme Partners LLP acquired a new position in shares of Moderna during the second quarter worth approximately $564,272,000. Wellington Management Group LLP boosted its position in shares of Moderna by 4.4% during the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after buying an additional 103,977 shares during the period. Merck & Co. Inc. acquired a new position in shares of Moderna during the second quarter worth approximately $161,642,545. Finally, Bamco Inc. NY bought a new position in Moderna in the 2nd quarter worth approximately $139,317,000. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 6.8%

Shares of NASDAQ:MRNA opened at $250.83 on Wednesday. The company has a 50 day moving average of $196.68 and a 200-day moving average of $93.60. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. The firm has a market cap of $101.49 billion, a P/E ratio of -35.33 and a beta of 1.16. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $280.80.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. During the same quarter last year, the business earned ($0.51) earnings per share. The business’s revenue for the quarter was up 29.2% on a year-over-year basis. As a group, analysts anticipate that Moderna, Inc. will post -5.69 earnings per share for the current fiscal year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
• Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
• Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
• Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
• Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Insider Buying and Selling at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on MRNA shares. Rothschild & Co Redburn cut Moderna from a “neutral” rating to a “sell” rating and raised their target price for the company from $40.00 to $81.00 in a research report on Thursday, September 3rd. Wolfe Research raised Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Moderna in a research report on Friday, September 25th. Berenberg Bank raised their price target on Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a report on Friday, September 11th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Moderna in a report on Friday, August 28th. They set a “hold” rating and a $125.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $113.75.

Moderna Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.